Uniting Biotech and Pharma Experts to Exchange Insights on Oligonucleotide Analytical Development and CMC. Despite milestone progress, such as Avidity securing breakthrough designation for their oligo conjugate, significant challenges persist across the oligo landscape in impurity profiling, drug characterisation, efficient scale-up, and regulatory alignment. Join 80+ industry experts from analytical development, process development, CMC, analytical chemistry, and quality control at the 4th Oligonucleotide Analytical Development and CMC Summit to collaborate, network and learn cutting-edge strategies that are tackling the unique challenges in oligo analytical development and CMC scale-up.